LAB - Standard Biotools exchanges all outstanding Series B convertible preferred stock for common stock
2024-03-18 09:37:53 ET
More on Standard BioTools
- Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript
- Standard BioTools expects over 10% growth in 2023 core revenue
- Standard BioTools, SomaLogic fall after shareholder nod for merger
- Seeking Alpha’s Quant Rating on Standard BioTools
- Historical earnings data for Standard BioTools